GlassScriptPhysician profile
Jonathan Isaacson
NPI 1184184764
$5,939.50
in general payments reported to CMS, 2019-2025
12 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.44 · 2023: $1,855 · 2024: $2,246 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,875 · Food and Beverage: $2,013 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,875.00 |
| Food and Beverage | $2,012.62 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $2,882.76 | 2024-2025 | Rytary, Crexont |
| Acadia Pharmaceuticals INC | $1,744.52 | 2023 | Nuplazid |
| Merz Pharmaceuticals, LLC | $496.20 | 2024-2025 | Xeomin |
| Mdd US Operations, LLC | $321.94 | 2024 | Gocovri |
| Neurocrine Biosciences, INC. | $213.94 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $88.41 | 2025 | Austedo Xr |
| Abbvie INC. | $62.43 | 2025 | |
| Kyowa Kirin, INC. | $43.44 | 2021 | |
| Boston Scientific Corporation | $35.20 | 2025 | Vercise |
| Biogen, INC. | $29.27 | 2025 | Skyclarys |
| Eisai INC. | $21.39 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Isaacson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.